Company
Emd Serono
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
20
13 still marketed
Novel approvals
7
Approvals since 2021
6
Originals and new uses
Phase 3 trials
42
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Pimjetmi approved NovelNov 10, 2026
- Bavencio new use Oct 11, 2024
- Tepmetko new use OrphanFeb 15, 2024
- Bavencio new use OrphanSep 6, 2023
- Bavencio new use Jul 15, 2022
- Tepmetko approved NovelAccelerated approvalPriority reviewOrphanFeb 3, 2021
- Bavencio new use Priority reviewJun 30, 2020
- Bavencio new use Breakthrough therapyPriority reviewOrphanMay 14, 2019
- Mavenclad approved Mar 29, 2019
- Bavencio new use OrphanOct 19, 2018
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)Pivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07549412 · 1,020 participants (planned) · Start May 6, 2026 · Primary completion Oct 16, 2029
Drug: Precemtabart tocentecan; Bevacizumab and 1 more · For: Metastatic Colorectal Cancer
Sites: San Francisco, California; Lone Tree, Colorado; Fort Myers, Florida · 116 sites in all
- A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]Pivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07840287 · 404 participants (planned) · Start Oct 22, 2026 · Primary completion Sep 1, 2031
Drug: Enpatoran · For: Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE)
Sites: Troy, Michigan
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)Pivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07355218 · 202 participants (planned) · Start Apr 1, 2026 · Primary completion May 25, 2029
Drug: Enpatoran; Placebo and 1 more · For: Systematic Lupus Erythematosus; Cutaneous Lupus Erythematosus
Sites: Upland, California; DeBary, Florida; Fort Lauderdale, Florida · 70 sites in all
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseasePivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07332481 · 202 participants (planned) · Start Mar 10, 2026 · Primary completion May 24, 2029
Drug: Enpatoran; Placebo and 1 more · For: Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE)
Sites: Los Angeles, California; Thousand Oaks, California; Cooper City, Florida · 74 sites in all
Marketed drugs (13)
Newest FDA action first.
- Pimjetmi Pimicotinib · 2026
- Bavencio Avelumab · 2017
- Serostim Somatropin · 1996
- Mavenclad Cladribine · 2019
- Cetrotide Cetrorelix Acetate · 2000
- Gonal-F Rff Redi-Ject Follitropin Alfa/Beta · 2004
- Tepmetko Tepotinib Hydrochloride · 2021
- Gonal-F Follitropin Alfa/Beta · 1997
- Gonal-F Follitropin Alfa/Beta · 2004
- Bavencio Avelumab · 2017
- Saizen Somatropin · 1996
- Ovidrel Choriogonadotropin Alfa · 2000
- Zorbtive Somatropin Recombinant · 2003
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.